<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868072</url>
  </required_header>
  <id_info>
    <org_study_id>BE118111814 / BN1-18-118</org_study_id>
    <nct_id>NCT03868072</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Bioequivalence of Pfizer Korea Inc. &quot;XELJANZ 5Mg Tablet&quot; in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical &quot;Chong Kun Dang Tofacitinib Tablet&quot; and Pfizer Korea Inc. &quot;XELJANZ 5Mg Tablet&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the
      bioequivalence of Chong Kun Dang Pharmaceutical &quot;Chong Kun Dang Tofacitinib Tablet&quot; and
      Pfizer Korea Inc. &quot;XELJANZ 5Mg Tablet&quot; in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of forty (40), following treatments are administered dosing in each
      period and wash-out period is a minimum of 1 week.

      Reference drug: XELJANZ 5Mg Tablet / Test drug: Chong Kun Dang Tofacitinib Tablet
      Pharmacokinetic blood samples are collected up to 12hrs. The pharmacokinetic characteristics
      and safety are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Actual">April 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Chong Kun Dang Tofacitinib Tablet and XELJANZ 5Mg Tablet</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.083, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Area under the Chong Kun Dang Tofacitinib Tablet / XELJANZ 5Mg Tablet concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Chong Kun Dang Tofacitinib Tablet and XELJANZ 5Mg Tablet</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.083, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>The maximum Chong Kun Dang Tofacitinib Tablet / XELJANZ 5Mg Tablet concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Reference/Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: XELJANZ 5Mg Tablet 1T
Period 2: Chong Kun Dang Tofacitinib Tablet 1T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test/Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Chong Kun Dang Tofacitinib Tablet 1T
Period 2: XELJANZ 5Mg Tablet 1T</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELJANZ 5Mg Tablet</intervention_name>
    <description>XELJANZ 5Mg Tablet 1T single oral administration under fasting</description>
    <arm_group_label>Reference/Test</arm_group_label>
    <arm_group_label>Test/Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chong Kun Dang Tofacitinib Tablet</intervention_name>
    <description>Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting</description>
    <arm_group_label>Reference/Test</arm_group_label>
    <arm_group_label>Test/Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subject older than 19 years at the screening

          2. Individuals who had 18 kg/m2 ≤ Body Mass Index(BMI) ≤ 30kg/m2

             * BMI = Weight(kg)/ Height(m)2

          3. Individuals without congenital/chronic diseases and without abnormal symptoms or
             diagnosis based on a medical examination(if necessary, EEG, ECG, chest X-ray,
             endoscope or upper gastrointestinal radiography)

          4. Individuals who were deemed to be appropriate as study subjects in accordance with the
             screening results (laboratory tests, ECG, chest X-ray etc.)

          5. Women who are not pregnant at physical examination

        Exclusion Criteria:

          1. Individuals who had enrolled to barbiturate's drugs by induction and inhibition of
             drug-metabolizing enzymes of drugs, such as drugs or excessive drinking within the 1
             month

          2. Individuals who had taken any medication within 10 days prior to the first day of
             dosing

          3. Individuals who were deemed to be inappropriate to participate in the study by the
             investigator

          4. Individuals who had participated of other clinical study or bioequivalence study
             within the 3 months prior to the first day of dosing

          5. Individuals who donated whole blood within the 2 months, or blood components within 2
             weeks prior to the first dose of the investigational product(s)

          6. Individuals who do not agree to the approved methods of double contraception and using
             spermicide for up to 7 days (only, 4 weeks for women who may be pregnant) after
             investigational product(s) administration (Double contraception: two or more of the
             use of condoms, intrauterine contraception, diaphragm, cervical cap, or a sexual
             partner who had been medically diagnosed infertility)

          7. Individuals with hypersensitivity to ingredients used in the investigational
             product(s)

          8. Patients with serious infection (e.g., Sepsis) or active infection including localized
             infection

          9. Patients with active tuberculosis

         10. Patients with severe hepatopathy

         11. Patients with an absolute neutrophil count (ANC) less than 500 cells/mm3

         12. Patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3

         13. Patients who have hemoglobin levels less than 8 g/dL

         14. Women who are pregnant or may be pregnant or lactating

         15. Patients with hereditary diseases of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption etc.

         16. Patients with nephropathy (BUN&lt;8 or BUN&gt;20 or Creatinine&gt;1.5)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bestian Hospital</name>
      <address>
        <city>Osong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

